Saturday 17 October 2026
Export RAPP’s income statement to Excel — free account
Rapport Therapeutics, Inc.
RAPP Healthcare Biotechnology
In the quarter to June 2026, EPS fell 58.7% and free cash flow fell 64.8%, each against the same quarter a year earlier.
27.57
2.00
−6.76%
Follow RAPP
Rapport Therapeutics, Inc. (RAPP) P/E ratio
Rapport Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2026 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IMCR Immunocore Holdings PLC Sponsored ADR compare | n/m |
| ANAB AnaptysBio, Inc. compare | n/m |
| ABSI Absci Corporation compare | n/m |
| ORIC Oric Pharmaceuticals, Inc. compare | n/m |
| INBX Inhibrx Biosciences, Inc. compare | n/m |
| RARE Ultragenyx Pharmaceutical Inc. compare | n/m |
| RAPP Rapport Therapeutics, Inc. | n/m |
| OMER Omeros Corporation compare | 9.5× |
| AAPG Ascentage Pharma Group International - Unsponsored ADR compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)